PIIL:SEC:NSE/BSE:43:2026-27 August 18, 2026

Management Commentary & Business Overview

Industry Context:

  • Global crop protection market showing early signs of demand stabilization
  • Industry undergoing structural shift toward safer, more sustainable technologies
  • Competitive edge moving toward innovation, process excellence, and commercialization capabilities
  • Domestic market began with El Nino, strong heatwaves, delayed sowing, and high inventory levels
  • Monsoon and sowing have picked up to par with last year levels

Strategic Initiatives:

  • Commissioned one of world's largest flow plants with advanced flow chemistry capabilities
  • Pharma business showing early positive signs of transforming into differentiated CRDMO organization
  • Hyderabad CRO facility established as center of excellence for drug discovery
  • QC lab commissioned in Italy site approved by regulators
  • Electronic and specialty chemicals showing continued trajectory with new queries and commercialization
  • Biologicals business expanding globally with acquisition of unique peptide platform

Innovation & R&D:

  • First NCE, Pioxaniliprole (insecticide) discovered in India, awaiting regulatory approvals for domestic launch
  • 90 molecules under various stages of progress, with 60% at advanced stage
  • R&D investment at 3-4% of revenue

Financial Performance Q1 FY27

Revenue: ₹17,023 million

Gross Margin: 57%

EBITDA: ₹3,693 million

EBITDA Margin: 22%

Expected ETR for FY27: ~24%

Business Segment Performance:

Agchem Export Business:

  • Faced near-term challenges reflecting global crop protection industry contraction
  • Volume decline of 8%, value decline of 12%
  • Maintains strong competitive position with innovation and R&D excellence

Domestic Agri Business:

  • 12% volume growth, 3% revenue growth despite challenging environment
  • Biologicals showed 50% YoY growth with 3-year CAGR of 15%
  • Market presence with 15,000 distributors and 150,000 retailers
  • Flagship brands (Nominee Gold, Brofreya, Biovita) maintain leadership positions

Balance Sheet & Capital Allocation:

  • Net working capital reduced by 19 days, releasing ₹300 crore cash
  • Net cash position: ₹38 billion (debt-free)
  • Capex guidance for FY27: ₹700-800 crore
  • Q1 Capex: ₹250 crore invested across manufacturing assets, new verticals, and innovation-led approaches

Operational Metrics

  • Order book: $1.2 billion (stable sequentially)
  • Contract assets: ₹750 crore
  • New products contribution in CSM segment: 16-18%

Product Launch Timeline

Pioxaniliprole (NCE Insecticide):

  • Domestic launch expected in FY27 (awaiting regulatory approvals)
  • Global registrations planned: one geography next year, another the year after

Biological Nematicide:

  • Registered in Brazil, Mexico, and US
  • Brazil market size: USD 750 million (nematocide market)
  • Target: double-digit market share in Brazil over 5-10 years
  • 500+ field trials, 1,000+ grower engagements globally

Other Product Launches FY27:

  • 4-5 molecules planned across Agchem, Electronic Chemicals, and Pharma/Health Sciences
  • Dicloromezotiaz for diamondback moth launch expected in coming season

Subsidiary Performance

  • Subsidiaries reported EBIT loss of ~₹120 crore
  • Pharma EBITDA loss: ~₹60 crore
  • Losses attributed to investments in new businesses (global Biologicals, Pharma)
  • Front-loading investment for market development activities (farmer interactions, demonstrations)

Guidance & Outlook

  • FY27 expected to be better than FY26
  • Revenue growth: low single digits (positive trajectory)
  • Recovery in exports expected in second half supported by new product launches
  • Gradual scale-up of pharma and global biologicals businesses
  • Maintain gross margins through optimization and agility

Q&A Highlights

  • Pricing pressure due to demand cycle challenges, input costs, and consumption patterns
  • Pharma business delays due to sequential customer project timelines
  • Electronic chemicals commercial plant operational with commercial supplies started
  • Exclusive partnership signed for integrated drug discovery with a biotech company
  • Target 2-3 more similar partnerships in CRDMO business